Open Access Open Access  Restricted Access Subscription or Fee Access

Advantages of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules in pain management

Shailendra Kapoor, MD

Abstract


No abstract

Full Text:

PDF

References


Badalamenti VC, Buckley JW, Smith ET: Safety of EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules: Review of postmarketing adverse events during the first year. J Opioid Manag. 2012; 8: 115-125.

Johnson F, Setnik B: Morphine sulfate and naltrexone hydrochloride extended-release capsules: Naltrexone release, pharmacodynamics, and tolerability. Pain Physician. 2011; 14: 391-406.

Johnson FK, Ciric S, Boudriau S, et al.: Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol. 2012; 52: 747-756.

Johnson F, Ciric S, Boudriau S, et al.: Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther. 2010; 27:846-58.

Webster LR, Brewer R, Wang C, et al.: Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage. 2010; 40: 734-746.

Farahmand S, Ahmadi O, Dehpour A, et al.: Does adding low doses of oral naltrexone to morphine alter the subsequent opioid requirements and side effects in trauma patients? Am J Emerg Med. 2012; 30: 75-78.




DOI: https://doi.org/10.5055/jom.2012.0117

Refbacks

  • There are currently no refbacks.